CARMILA : Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L.233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des marchés financiers
Regulatory News:
CARMILA (Paris:CARM):
Date | Nombre d’actions composant lecapital social | Nombre réel de droits de vote(déduction faite des actions auto-détenues) | Nombre théorique de droits devote (y compris les actions auto-détenues)* |
31 mai 2024 | 142 441 073 | 142 338 718 | 142 441 073 |
*en application de l’article 223-11 du Règlement général del’Autorité des marchés financiers.
CARMILA
Société anonyme au capital de 854.646.438 euros
Siège social : 25, rue d’Astorg, 75008 Paris
RCS Paris 381 844 471
Consultez laversion source sur businesswire.com: https://www.businesswire.com/news/home/20240605621722/fr/
CARMILA
Carisma Therapeutics (NASDAQ:CARM)
Historical Stock Chart
From May 2024 to Jun 2024
Carisma Therapeutics (NASDAQ:CARM)
Historical Stock Chart
From Jun 2023 to Jun 2024
 | {{bbMessage.M_Alias}}{{bbMessage.MSG_Date}}{{bbMessage.HowLongAgo}}{{bbMessage.MSG_ID}}{{bbMessage.MSG_Subject}} |
Loading Messages....
Carisma Therapeutics Inc News
Loading Messages....
`,data() {return {tabs: [] };},created() {this.tabs = this.$children;},methods: {selectTab(selectedTab) {this.tabs.forEach(tab => {tab.isActive = (tab.name == selectedTab.name);});}}});Vue.component('tab', {template: `
`,props: {name: { required: true },selected: { default: false}},data() {return {isActive: false};},computed: {href() {return '#' + this.name.toLowerCase().replace(/ /g, '-');}},mounted() {this.isActive = this.selected;}});Vue.component('newslist', {template: `
FEATURED
•{{ article.source }} • {{ article.date}} {{article.time}}
`,props: {source: { required: true },rawarticles: { required: true },limit: { default: 12 }},methods: {processData: function(articles){if(articles.length > this.limit){articles = articles.slice(0, this.limit);}this.articles = articles;this.loaded = true;Vue.nextTick(function(){});},stripRedudancies: function(articles){return _.uniqBy(articles, "headline");}},data() {return {loaded: false,articles: []};},mounted() {this.processData(this.rawarticles);}});new Vue({el: '#nw-news-widget',data: {loaded: false,availableTabs: {"Press Releases": [{"headline":"CARMILA:\u00a0Information Concerning the Total Number of Voting Rights and Share","short_text":"\nprovided pursuant to article L.233-8 II of the Code de commerce (French Commercial Code) and article 223-16 of the R\u00e8glement g\u00e9n\u00e9ral de l\u2019Autorit\u00e9 des march\u00e9s financiers (General regulation of...","one_line_short_text":"\nprovided pursuant to article L.233-8 II of the Code de commerce (French Commercial Code) and article 223-16 of the R\u00e8glement g\u00e9n\u00e9ral de...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/carisma-therapeutics-CARM\/stock-news\/93991720\/carmila-information-concerning-the-total-number-o","source":"Business Wire","source_logo":"\/common\/images\/news-sources\/bw.png","tags":[],"timestamp":1717602300,"date":"Wed Jun 05, 2024 ","time":"11:45 AM (9 hours ago)","full_date":"June 5, 2024 11:45 AM","post_time":"9 hours ago","article_id":93991720,"source_id":"bw","media_url":null,"press_release":true},{"headline":"Carisma Therapeutics to Participate in the Jefferies Global Healthcare Conference","short_text":" Carisma Therapeutics to Participate in the Jefferies Global Healthcare Conference\nPR Newswire\nPHILADELPHIA, May 30, 2024 PHILADELPHIA, May 30, 2024 \/PRNewswire\/ -- Carisma Therapeutics...","one_line_short_text":" Carisma Therapeutics to Participate in the Jefferies Global Healthcare Conference\nPR Newswire\nPHILADELPHIA, May 30, 2024 PHILADELPHIA, May 30...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/carisma-therapeutics-CARM\/stock-news\/93950336\/carisma-therapeutics-to-participate-in-the-jefferi","source":"PR Newswire (US)","source_logo":"\/common\/images\/news-sources\/prnus.png","tags":[],"timestamp":1717068600,"date":"Thu May 30, 2024 ","time":"7:30 AM (7 days ago)","full_date":"May 30, 2024 7:30 AM","post_time":"May 30 2024","article_id":93950336,"source_id":"prnus","media_url":null,"press_release":true},{"headline":"Form SC 13D\/A - General statement of acquisition of beneficial ownership: [Amend]","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/carisma-therapeutics-CARM\/stock-news\/93938030\/form-sc-13d-a-general-statement-of-acquisition-o","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1716939596,"date":"Tue May 28, 2024 ","time":"7:39 PM (1 week ago)","full_date":"May 28, 2024 7:39 PM","post_time":"May 28 2024","article_id":93938030,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte","short_text":" Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte\nPR Newswire\nPHILADELPHIA, May 16, 2024 CT-0525 is the first...","one_line_short_text":" Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte\nPR...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/carisma-therapeutics-CARM\/stock-news\/93867285\/carisma-therapeutics-announces-first-patient-dosed","source":"PR Newswire (US)","source_logo":"\/common\/images\/news-sources\/prnus.png","tags":[],"timestamp":1715859000,"date":"Thu May 16, 2024 ","time":"7:30 AM (3 weeks ago)","full_date":"May 16, 2024 7:30 AM","post_time":"May 16 2024","article_id":93867285,"source_id":"prnus","media_url":null,"press_release":true},{"headline":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/carisma-therapeutics-CARM\/stock-news\/93814177\/form-10-q-quarterly-report-sections-13-or-15d","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1715255573,"date":"Thu May 09, 2024 ","time":"7:52 AM (4 weeks ago)","full_date":"May 9, 2024 7:52 AM","post_time":"May 09 2024","article_id":93814177,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/carisma-therapeutics-CARM\/stock-news\/93814093\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1715254862,"date":"Thu May 09, 2024 ","time":"7:41 AM (4 weeks ago)","full_date":"May 9, 2024 7:41 AM","post_time":"May 09 2024","article_id":93814093,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights","short_text":" Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights\nPR Newswire\nPHILADELPHIA, May 9, 2024 Announced CT-0525 as lead product candidate for anti-HER2...","one_line_short_text":" Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights\nPR Newswire\nPHILADELPHIA, May 9, 2024 Announced...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/carisma-therapeutics-CARM\/stock-news\/93813652\/carisma-therapeutics-reports-first-quarter-2024-fi","source":"PR Newswire (US)","source_logo":"\/common\/images\/news-sources\/prnus.png","tags":[],"timestamp":1715254200,"date":"Thu May 09, 2024 ","time":"7:30 AM (4 weeks ago)","full_date":"May 9, 2024 7:30 AM","post_time":"May 09 2024","article_id":93813652,"source_id":"prnus","media_url":null,"press_release":true},{"headline":"Carmila: Withdrawal of funds for the liquidity contract","short_text":"\nRegulatory News: On November 3rd, 2023, Carmila SA (Paris:CARM) (ISIN: FR0010828137) has entered into a Liquidity Contract with Kepler Cheuvreux (the \"Contract\"). This Contract, with an initial...","one_line_short_text":"\nRegulatory News: On November 3rd, 2023, Carmila SA (Paris:CARM) (ISIN: FR0010828137) has entered into a Liquidity Contract with Kepler Cheuvreux...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/carisma-therapeutics-CARM\/stock-news\/93804658\/carmila-withdrawal-of-funds-for-the-liquidity-con","source":"Business Wire","source_logo":"\/common\/images\/news-sources\/bw.png","tags":[],"timestamp":1715183100,"date":"Wed May 08, 2024 ","time":"11:45 AM (4 weeks ago)","full_date":"May 8, 2024 11:45 AM","post_time":"May 08 2024","article_id":93804658,"source_id":"bw","media_url":null,"press_release":true},{"headline":"Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024","short_text":" Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024\nPR Newswire\nPHILADELPHIA, May 8, 2024 Novel...","one_line_short_text":" Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/carisma-therapeutics-CARM\/stock-news\/93801966\/carisma-therapeutics-presents-preclinical-proof-of","source":"PR Newswire (US)","source_logo":"\/common\/images\/news-sources\/prnus.png","tags":[],"timestamp":1715167800,"date":"Wed May 08, 2024 ","time":"7:30 AM (4 weeks ago)","full_date":"May 8, 2024 7:30 AM","post_time":"May 08 2024","article_id":93801966,"source_id":"prnus","media_url":null,"press_release":true},{"headline":"CARMILA: Information Concerning the Total Number of Voting Rights and Share","short_text":"\nprovided pursuant to article L.233-8 II of the Code de commerce (French Commercial Code) and article 223-16 of the R\u00e8glement g\u00e9n\u00e9ral de l\u2019Autorit\u00e9 des march\u00e9s financiers (General regulation of...","one_line_short_text":"\nprovided pursuant to article L.233-8 II of the Code de commerce (French Commercial Code) and article 223-16 of the R\u00e8glement g\u00e9n\u00e9ral de...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/carisma-therapeutics-CARM\/stock-news\/93793437\/carmila-information-concerning-the-total-number-o","source":"Business Wire","source_logo":"\/common\/images\/news-sources\/bw.png","tags":[],"timestamp":1715096700,"date":"Tue May 07, 2024 ","time":"11:45 AM (4 weeks ago)","full_date":"May 7, 2024 11:45 AM","post_time":"May 07 2024","article_id":93793437,"source_id":"bw","media_url":null,"press_release":true},{"headline":"Carisma Therapeutics to Participate in The Citizens JMP Life Sciences Conference","short_text":" Carisma Therapeutics to Participate in The Citizens JMP Life Sciences Conference\nPR Newswire\nPHILADELPHIA, May 6, 2024 PHILADELPHIA, May 6, 2024 \/PRNewswire\/ -- Carisma Therapeutics Inc.\u00a0(Nasdaq:...","one_line_short_text":" Carisma Therapeutics to Participate in The Citizens JMP Life Sciences Conference\nPR Newswire\nPHILADELPHIA, May 6, 2024 PHILADELPHIA, May 6, 2024...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/carisma-therapeutics-CARM\/stock-news\/93781418\/carisma-therapeutics-to-participate-in-the-citizen","source":"PR Newswire (US)","source_logo":"\/common\/images\/news-sources\/prnus.png","tags":[],"timestamp":1714995000,"date":"Mon May 06, 2024 ","time":"7:30 AM (1 month ago)","full_date":"May 6, 2024 7:30 AM","post_time":"May 06 2024","article_id":93781418,"source_id":"prnus","media_url":null,"press_release":true}],"All News": [{"headline":"CARMILA:\u00a0Information Concerning the Total Number of Voting Rights and Share","short_text":"\nprovided pursuant to article L.233-8 II of the Code de commerce (French Commercial Code) and article 223-16 of the R\u00e8glement g\u00e9n\u00e9ral de l\u2019Autorit\u00e9 des march\u00e9s financiers (General regulation of...","one_line_short_text":"\nprovided pursuant to article L.233-8 II of the Code de commerce (French Commercial Code) and article 223-16 of the R\u00e8glement g\u00e9n\u00e9ral de...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/carisma-therapeutics-CARM\/stock-news\/93991720\/carmila-information-concerning-the-total-number-o","source":"Business Wire","source_logo":"\/common\/images\/news-sources\/bw.png","tags":[],"timestamp":1717602300,"date":"Wed Jun 05, 2024 ","time":"11:45 AM (9 hours ago)","full_date":"June 5, 2024 11:45 AM","post_time":"9 hours ago","article_id":93991720,"source_id":"bw","media_url":null,"press_release":true},{"headline":"Carisma Therapeutics to Participate in the Jefferies Global Healthcare Conference","short_text":" Carisma Therapeutics to Participate in the Jefferies Global Healthcare Conference\nPR Newswire\nPHILADELPHIA, May 30, 2024 PHILADELPHIA, May 30, 2024 \/PRNewswire\/ -- Carisma Therapeutics...","one_line_short_text":" Carisma Therapeutics to Participate in the Jefferies Global Healthcare Conference\nPR Newswire\nPHILADELPHIA, May 30, 2024 PHILADELPHIA, May 30...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/carisma-therapeutics-CARM\/stock-news\/93950336\/carisma-therapeutics-to-participate-in-the-jefferi","source":"PR Newswire (US)","source_logo":"\/common\/images\/news-sources\/prnus.png","tags":[],"timestamp":1717068600,"date":"Thu May 30, 2024 ","time":"7:30 AM (7 days ago)","full_date":"May 30, 2024 7:30 AM","post_time":"May 30 2024","article_id":93950336,"source_id":"prnus","media_url":null,"press_release":true},{"headline":"Form SC 13D\/A - General statement of acquisition of beneficial ownership: [Amend]","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/carisma-therapeutics-CARM\/stock-news\/93938030\/form-sc-13d-a-general-statement-of-acquisition-o","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1716939596,"date":"Tue May 28, 2024 ","time":"7:39 PM (1 week ago)","full_date":"May 28, 2024 7:39 PM","post_time":"May 28 2024","article_id":93938030,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte","short_text":" Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte\nPR Newswire\nPHILADELPHIA, May 16, 2024 CT-0525 is the first...","one_line_short_text":" Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte\nPR...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/carisma-therapeutics-CARM\/stock-news\/93867285\/carisma-therapeutics-announces-first-patient-dosed","source":"PR Newswire (US)","source_logo":"\/common\/images\/news-sources\/prnus.png","tags":[],"timestamp":1715859000,"date":"Thu May 16, 2024 ","time":"7:30 AM (3 weeks ago)","full_date":"May 16, 2024 7:30 AM","post_time":"May 16 2024","article_id":93867285,"source_id":"prnus","media_url":null,"press_release":true},{"headline":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/carisma-therapeutics-CARM\/stock-news\/93814177\/form-10-q-quarterly-report-sections-13-or-15d","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1715255573,"date":"Thu May 09, 2024 ","time":"7:52 AM (4 weeks ago)","full_date":"May 9, 2024 7:52 AM","post_time":"May 09 2024","article_id":93814177,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/carisma-therapeutics-CARM\/stock-news\/93814093\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1715254862,"date":"Thu May 09, 2024 ","time":"7:41 AM (4 weeks ago)","full_date":"May 9, 2024 7:41 AM","post_time":"May 09 2024","article_id":93814093,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights","short_text":" Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights\nPR Newswire\nPHILADELPHIA, May 9, 2024 Announced CT-0525 as lead product candidate for anti-HER2...","one_line_short_text":" Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights\nPR Newswire\nPHILADELPHIA, May 9, 2024 Announced...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/carisma-therapeutics-CARM\/stock-news\/93813652\/carisma-therapeutics-reports-first-quarter-2024-fi","source":"PR Newswire (US)","source_logo":"\/common\/images\/news-sources\/prnus.png","tags":[],"timestamp":1715254200,"date":"Thu May 09, 2024 ","time":"7:30 AM (4 weeks ago)","full_date":"May 9, 2024 7:30 AM","post_time":"May 09 2024","article_id":93813652,"source_id":"prnus","media_url":null,"press_release":true},{"headline":"Carmila: Withdrawal of funds for the liquidity contract","short_text":"\nRegulatory News: On November 3rd, 2023, Carmila SA (Paris:CARM) (ISIN: FR0010828137) has entered into a Liquidity Contract with Kepler Cheuvreux (the \"Contract\"). This Contract, with an initial...","one_line_short_text":"\nRegulatory News: On November 3rd, 2023, Carmila SA (Paris:CARM) (ISIN: FR0010828137) has entered into a Liquidity Contract with Kepler Cheuvreux...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/carisma-therapeutics-CARM\/stock-news\/93804658\/carmila-withdrawal-of-funds-for-the-liquidity-con","source":"Business Wire","source_logo":"\/common\/images\/news-sources\/bw.png","tags":[],"timestamp":1715183100,"date":"Wed May 08, 2024 ","time":"11:45 AM (4 weeks ago)","full_date":"May 8, 2024 11:45 AM","post_time":"May 08 2024","article_id":93804658,"source_id":"bw","media_url":null,"press_release":true},{"headline":"Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024","short_text":" Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024\nPR Newswire\nPHILADELPHIA, May 8, 2024 Novel...","one_line_short_text":" Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/carisma-therapeutics-CARM\/stock-news\/93801966\/carisma-therapeutics-presents-preclinical-proof-of","source":"PR Newswire (US)","source_logo":"\/common\/images\/news-sources\/prnus.png","tags":[],"timestamp":1715167800,"date":"Wed May 08, 2024 ","time":"7:30 AM (4 weeks ago)","full_date":"May 8, 2024 7:30 AM","post_time":"May 08 2024","article_id":93801966,"source_id":"prnus","media_url":null,"press_release":true},{"headline":"CARMILA: Information Concerning the Total Number of Voting Rights and Share","short_text":"\nprovided pursuant to article L.233-8 II of the Code de commerce (French Commercial Code) and article 223-16 of the R\u00e8glement g\u00e9n\u00e9ral de l\u2019Autorit\u00e9 des march\u00e9s financiers (General regulation of...","one_line_short_text":"\nprovided pursuant to article L.233-8 II of the Code de commerce (French Commercial Code) and article 223-16 of the R\u00e8glement g\u00e9n\u00e9ral de...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/carisma-therapeutics-CARM\/stock-news\/93793437\/carmila-information-concerning-the-total-number-o","source":"Business Wire","source_logo":"\/common\/images\/news-sources\/bw.png","tags":[],"timestamp":1715096700,"date":"Tue May 07, 2024 ","time":"11:45 AM (4 weeks ago)","full_date":"May 7, 2024 11:45 AM","post_time":"May 07 2024","article_id":93793437,"source_id":"bw","media_url":null,"press_release":true},{"headline":"Carisma Therapeutics to Participate in The Citizens JMP Life Sciences Conference","short_text":" Carisma Therapeutics to Participate in The Citizens JMP Life Sciences Conference\nPR Newswire\nPHILADELPHIA, May 6, 2024 PHILADELPHIA, May 6, 2024 \/PRNewswire\/ -- Carisma Therapeutics Inc.\u00a0(Nasdaq:...","one_line_short_text":" Carisma Therapeutics to Participate in The Citizens JMP Life Sciences Conference\nPR Newswire\nPHILADELPHIA, May 6, 2024 PHILADELPHIA, May 6, 2024...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/carisma-therapeutics-CARM\/stock-news\/93781418\/carisma-therapeutics-to-participate-in-the-citizen","source":"PR Newswire (US)","source_logo":"\/common\/images\/news-sources\/prnus.png","tags":[],"timestamp":1714995000,"date":"Mon May 06, 2024 ","time":"7:30 AM (1 month ago)","full_date":"May 6, 2024 7:30 AM","post_time":"May 06 2024","article_id":93781418,"source_id":"prnus","media_url":null,"press_release":true}],"Preferred Contributors": ""}},created: function () {this.loaded = true;Vue.nextTick(function(){});}});});
More Carisma Therapeutics Inc News Articles
